ReviewJournal of gastroenterology2020
Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments.
Review in Journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 7 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- The prognostic value of sarcopenia in acute-on-chronic liver failure: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Effects of Exercise Training on Muscle Mass and Physical Function in Patients with Hepatocellular Carcinoma After Diagnosis: A Systematic Review.Digestive diseases and sciences · 2024Pooled it
- Pooled it
- Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis.Scientific reports · 2023Pooled it
- Low skeletal muscle mass and post-operative complications after surgery for liver malignancies: a meta-analysis.Langenbeck's archives of surgery · 2022Pooled it
- Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review.Frontiers in oncology · 2022Pooled it
- Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology (Baltimore, Md.) · 2021Guideline
- Bioimpedance Analysis to Predict Clinical Outcomes of Liver Cirrhosis in a Prospective Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- The impact of sarcopenia on short-term efficacy, toxic and adverse reactions, and prognosis in patients with non-small cell lung cancer undergoing concurrent chemoradiotherapy.Frontiers in nutrition · 2026Article
- "Noninvasive predictive marker for esophageal variceal bleeding".BMC gastroenterology · 2025Article
- Sarcopenic Obesity and Sarcopenic Visceral Obesity, Calculated Using the Skeletal Muscle İndex and Visceral Fat İndex at the L3 Vertebra Level, Do Not Predict Survival Rates in Endometrial Cancer Patients.Journal of clinical medicine · 2025Article
- Review
- Impact of Preoperative Comprehensive Body Composition on Postoperative Outcomes in Patients with Esophageal Cancer.Journal of clinical medicine · 2025Article
- ALBI-sarcopenia score as a predictor of treatment outcomes in hepatocellular carcinoma.Scientific reports · 2025Article
- Postoperative Changes in Body Composition Predict Long-Term Prognosis in Patients with Gastric Cancer.Cancers · 2025Article
- CT-based skeletal muscle loss predicts long term prognosis in patients with distal cholangiocarcinoma undergone pancreaticoduodenectomy.Scientific reports · 2025Article
- Imaging-based assessment of muscles and malnutrition predict prognosis in patients with primary hepatocellular carcinoma.PloS one · 2025Article
- Impact of body composition metrics extracted from QCT and the corresponding nomogram on the evaluation of survival prognosis in AML patients.Frontiers in oncology · 2025Article
- Article
- Textbook outcome and nomogram-guided approaches for enhancing surgical success in elderly HCC patients: Deciphering the influence of sarcopenia.Updates in surgery · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Changes in body composition are associated with poor outcomes in cancer patients including hepatocellular carcinoma (HCC). Sarcopenia, defined as the loss of skeletal muscle mass, quality and function, has been associated with a higher rate of complications and recurrences in patients with cirrhosis and HCC. The assessment of patient general status before HCC treatment, including the presence of sarcopenia, is a key-point for achieving therapy tolerability and to avoid short- and long-term complications leading to poor patients' survival. Thus, we aimed to review the current literature evaluating the role of sarcopenia assessment related to HCC treatments and to critically provide the clinicians with the most recent and valuable evidence. As a result, sarcopenia can be predictive of poor outcomes in patients undergoing liver resection, transplantation and systemic therapies, offering the chance to clinicians to improve the muscular status of these patients, especially those with high-grade sarcopenia at high risk of mortality. Further studies are needed to clarify the predictive value of sarcopenia in other HCC treatment settings and to evaluate its role as an additional staging tool for identifying the most appropriate treatment. Besides, interventional studies aiming at increasing the skeletal muscle mass for reducing complications and increasing the survival in patients with HCC are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.